- ISIN
- US03237H1014
- CUSIP
- 03237H101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 7, 2022
Highlights
- Market Cap
- $2.26B
- Enterprise Value
- $2.04B
- EPS (TTM)
- -$1.51
- Gross Profit (TTM)
- -$20.10M
- EBITDA (TTM)
- -$150.30M
- Year Range
- $7.48 - $20.94
- Target Price
- $24.50
- ROA (TTM)
- -51.13%
- ROE (TTM)
- -54.95%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $31.68M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AMLX Performance Chart
Amylyx Pharmaceuticals, Inc. (AMLX) is up 68.1% since the beginning of the year. At $20 per share, AMLX is trading 3.0% below its 52-week high of $21.
Loading charts...
Compare this symbol against anything
Returns By Period
Amylyx Pharmaceuticals, Inc. (AMLX) has returned 68.13% so far this year and 163.25% over the past 12 months.
Amylyx Pharmaceuticals, Inc.
- 1D
- -2.12%
- 1M
- 11.17%
- 6M
- 42.13%
- YTD
- 68.13%
- 1Y
- 163.25%
- 3Y*
- -4.58%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -0.73%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
AMLX Monthly Returns History
Based on dividend-adjusted daily data since Jan 7, 2022, AMLX's average daily return is +0.21%, while the average monthly return is +5.08%. At this rate, an investment would double in approximately 1.2 years.
Historically, 58% of months were positive and 42% were negative. The best month was Jun 2022 with a return of +116.7%, while the worst month was Mar 2024 at -84.9%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.
On a daily basis, AMLX closed higher 51% of trading days. The best single day was Sep 8, 2022 with a return of +51.0%, while the worst single day was Mar 8, 2024 at -82.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.29% | 6.16% | -8.37% | 15.11% | -10.31% | 25.16% | 13.08% | 68.13% | |||||
| 2025 | -3.44% | -10.14% | 7.93% | 44.35% | 0.78% | 24.47% | 25.27% | 16.81% | 44.88% | 2.50% | 7.54% | -19.36% | 219.58% |
| 2024 | 8.70% | 17.81% | -84.93% | -36.27% | -4.97% | 10.47% | 8.42% | 7.77% | 45.95% | 66.67% | 2.59% | -31.77% | -74.32% |
| 2023 | 6.06% | -11.15% | -15.74% | -3.20% | -13.06% | -12.64% | 8.72% | -8.06% | -15.07% | -10.92% | -13.18% | 3.95% | -60.16% |
| 2022 | 10.38% | 41.93% | -60.94% | -29.96% | -1.22% | 116.65% | 40.13% | -6.48% | 11.53% | 26.71% | 7.57% | -3.70% | 75.95% |
Benchmark Metrics
Amylyx Pharmaceuticals, Inc. has an annualized alpha of 46.42%, beta of 1.21, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 07, 2022.
- This stock tended to rise when S&P 500 Index fell (downside capture of -90.12%), but participation in market rallies was also limited (-30.49%) - a profile typical of counter-cyclical assets.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 46.42%
- Beta
- 1.21
- R²
- 0.05
- Upside Capture
- -30.49%
- Downside Capture
- -90.12%
Return for Risk
Risk / Return Rank
AMLX ranks 93 for risk / return — above 93% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AMLX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.10 | ||
| Sortino ratioReturn per unit of downside risk | +1.09 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.25 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 5.03 | 2.00 | +3.02 |
| Martin ratioReturn relative to average drawdown | 10.76 | 8.49 | +2.27 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Amylyx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Amylyx Pharmaceuticals, Inc. was 96.04%, occurring on Jun 18, 2024. The portfolio has not yet recovered.
The current Amylyx Pharmaceuticals, Inc. drawdown is 50.38%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.04%Jun 2024 | 1y 4mo | — | 3y 6moJan 2023 - now | — |
-79.18%May 2022 | 2mo 11d | 5mo 2d | 7mo 13dMar 2022 - Oct 2022 | Bear market2022 |
-20.38%Jan 2022 | 3d | 3d | 6dJan 2022 - Jan 2022 | Bear market2022 |
-17.59%Feb 2022 | 9d | 7d | 16dFeb 2022 - Feb 2022 | Bear market2022 |
-15.23%Dec 2022 | 17d | 1mo 6d | 1mo 23dDec 2022 - Jan 2023 | Bear market2022 |
Drawdown Indicators
| AMLX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.04% | -56.78% | -39.26% |
Max Drawdown (1Y)Largest decline over 1 year | -30.61% | -9.10% | -21.51% |
Max Drawdown (3Y)Largest decline over 3 years | -92.82% | -18.90% | -73.92% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -50.38% | -1.58% | -48.80% |
Average DrawdownAverage peak-to-trough decline | -59.30% | -10.70% | -48.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.27% | 2.14% | +12.13% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Amylyx Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Amylyx Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AMLX in comparison with other companies in the Biotechnology industry. Currently, AMLX has a P/B value of 8.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AMLX
Add Amylyx Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AMLX